Sep 16, 2026, 8:30 AM EDT · 6 weeks ago Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
Aug 28, 2026, 4:25 PM EDT · 2 months ago Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update
Jul 7, 2026, 8:30 AM EDT · 3 months ago Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
May 19, 2026, 8:45 AM EDT · 5 months ago Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21
May 7, 2026, 8:30 AM EDT · 5 months ago Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation
May 5, 2026, 8:30 AM EDT · 6 months ago Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
2026-04-20T14:01:13.000Z · 6 months ago Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002
Apr 13, 2026, 8:30 AM EDT · 6 months ago Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
2026-03-25T22:35:16.000Z · 7 months ago Oragenics receives audit opinion with going concern explanation
Mar 25, 2026, 6:30 PM EDT · 7 months ago Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
Mar 12, 2026, 8:30 AM EDT · 7 months ago ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
2026-03-11T12:45:33.000Z · 7 months ago Oragenics explores potential acquisition of additional assets in CNS space
Mar 11, 2026, 8:30 AM EDT · 7 months ago ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
2026-03-10T12:42:00.000Z · 7 months ago Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
Mar 10, 2026, 8:30 AM EDT · 7 months ago Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Feb 9, 2026, 8:30 AM EST · 8 months ago Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
2026-02-03T13:40:46.000Z · 9 months ago Oragenics partners with Duck Flats Pharma to support FDA IND trial design
Feb 3, 2026, 8:30 AM EST · 9 months ago Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
Oct 21, 2025, 8:00 AM EDT · 1 year ago Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
2025-10-07T13:20:29.000Z · 1 year ago Oragenics, Receptor.AI partner to accelerate pipeline development
Oct 7, 2025, 8:30 AM EDT · 1 year ago Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
2025-07-31T12:52:03.000Z · 1 year ago Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial
2025-07-16T12:45:56.000Z · 1 year ago Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002
Jul 16, 2025, 8:39 AM EDT · 1 year ago Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
2025-07-01T12:41:48.000Z · 1 year ago Oragenics prices 800,000 shares of Preferred Stock at $25.00 in public offering
Jul 1, 2025, 8:31 AM EDT · 1 year ago Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
May 13, 2025, 8:30 AM EDT · 1 year ago Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
May 12, 2025, 8:30 AM EDT · 1 year ago Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Apr 7, 2025, 4:30 PM EDT · 1 year ago Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
Mar 27, 2025, 8:30 AM EDT · 1 year ago Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
Mar 18, 2025, 5:33 PM EDT · 1 year ago Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
Mar 6, 2025, 9:30 AM EST · 1 year ago Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
Feb 25, 2025, 8:30 AM EST · 1 year ago Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
Feb 11, 2025, 8:30 AM EST · 1 year ago Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Feb 5, 2025, 8:15 AM EST · 1 year ago Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
Jan 21, 2025, 8:15 AM EST · 1 year ago Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
Dec 16, 2024, 8:09 AM EST · 1 year ago Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
Oct 18, 2024, 8:30 AM EDT · 2 years ago Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
Oct 9, 2024, 7:30 AM EDT · 2 years ago Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
Oct 8, 2024, 8:45 AM EDT · 2 years ago Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Aug 21, 2024, 8:45 AM EDT · 2 years ago Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
Aug 16, 2024, 4:30 PM EDT · 2 years ago Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Aug 14, 2024, 8:30 AM EDT · 2 years ago Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Aug 12, 2024, 8:30 AM EDT · 2 years ago Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
Aug 8, 2024, 8:45 AM EDT · 2 years ago Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Jun 27, 2024, 8:30 AM EDT · 2 years ago Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
May 22, 2024, 8:00 AM EDT · 2 years ago Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
May 17, 2024, 8:00 AM EDT · 2 years ago Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
Apr 19, 2024, 5:50 PM EDT · 2 years ago Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Mar 18, 2024, 7:00 AM EDT · 2 years ago Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
Mar 5, 2024, 7:45 AM EST · 2 years ago Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion